Figure 3 from A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor–Positive Metastatic Breast Cancer

<jats:p>&lt;p&gt;&lt;b&gt;A–E,&lt;/b&gt; Survival analysis. &lt;b&gt;A–D,&lt;/b&gt; Kaplan–Meier survival and PFS curves of all patients (&lt;b&gt;A&lt;/b&gt; and &lt;b&gt;C&lt;/b&gt;) and evaluable patients (&lt;b&gt;B&lt;/b&gt; and &lt;b&gt;D&lt;/b&gt;). &lt;b&gt;E,&lt;/b&gt; Survival waterfall plot of all patients with best response labels: CR, PR, SD, PD, and NE (patients who did not reach the third cycle of PEM). A heart symbol denotes patient still alive at data lock. (a) In patient 7, the PEM infusion was aborted because of acute GI bleeding. She was considered NE and went on to receive PLD only. (b) Patient 37 was still treated within the Keydox study at data lock.&lt;/p&gt;</jats:p>